|
27 Sep 2019 |
BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial
|
|
27 Sep 2019 |
Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
|
|
25 Sep 2019 |
Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials
|
|
25 Sep 2019 |
Galapagos initiates Phase 1 trial for second Toledo compound
|
|
25 Sep 2019 |
Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801
|
|
25 Sep 2019 |
OCTIMET Expands Ongoing Proof of Concept Study to Evaluate the Combination of Highly Selective MET Kinase Inhibitor OMO-1 with EGFR TKIs
|
|
25 Sep 2019 |
MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis
|
|
25 Sep 2019 |
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis
|
|
25 Sep 2019 |
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
|
|
25 Sep 2019 |
NORTHSEA THERAPEUTICS: NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
|
|
24 Sep 2019 |
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU
|
|
24 Sep 2019 |
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
|
|
24 Sep 2019 |
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
|
|
24 Sep 2019 |
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
|
|
24 Sep 2019 |
Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
|
|
24 Sep 2019 |
ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
|
|
24 Sep 2019 |
Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibitor, Targeting Advanced Breast Cancer
|
|
24 Sep 2019 |
Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back
|
|
24 Sep 2019 |
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
|
|
24 Sep 2019 |
Cerevel Therapeutics Announces Positive Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease
|
|
23 Sep 2019 |
Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes
|
|
20 Sep 2019 |
XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)
|
|
20 Sep 2019 |
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
|
|
20 Sep 2019 |
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
|
|
20 Sep 2019 |
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union
|
